The influence of methylene levels during severe sepsis blue infusion on cytokine

Basit Öğe Kaydı
dc.contributor.authorMemis, D
dc.contributor.authorKaramanlioglu, B
dc.contributor.authorYuksel, M
dc.contributor.authorGemlik, I
dc.contributor.authorPamukcu, Z
dc.date.accessioned2024-06-12T11:08:26Z
dc.date.available2024-06-12T11:08:26Z
dc.date.issued2002
dc.departmentTrakya Üniversitesien_US
dc.description.abstractThe aim of our study was to assess the effect of methylene blue infusion on plasma levels of cytokines in severe sepsis. In a prospective, randomized, double-blind, placebo-controlled study, patients received either methylene blue 0.5 mg.kg(-1).h(-1) (MB group, n=15) or similar volume of isotonic saline (control group, n=15) IV for 6 hours. Plasma concentrations of tumour necrosis factor-alpha, interleukin-1, interleukin-2 receptor, interleukin-6, interleukin-8 were measured by sensitive immunoassays at basal (15 min before start of the study), immediately after, and at 24 and 48 hours after methylene blue infusion. We evaluated haemodynamic parameters (mean arterial pressure, heart rate), blood gases, methaemoglobin levels, and biochemical parameters at the same time. Methylene blue administration had no significant effect on plasma cytokine levels, blood gases and biochemical parameters. When compared to placebo infusion in controls, methylene blue administration resulted in significantly higher mean arterial pressure (85+/-14 mmHg vs 74.1+/-10.3 mmHg; P<0.01), and methaemoglobin levels (1.06+/-0.22% vs 0.9+/-0.05%; P<0.05). Furthermore, comparison with baseline levels revealed significantly increased both mean arterial pressure (85+/-14 mmHg and 74.1+/-10.2 mmHg, P<0.05) and methaemoglobin levels (1.06+/-0.22% and 0.88+/-0.06%; P<0.05) in MB group. There was no difference in mortality rates between the groups. We found that methylene blue infusion did not change cytokine levels or outcome in severe sepsis. The administration of methylene blue, however, resulted in a transient increase in arterial pressure. Because of the limited size of the present study, and the short period of observation, our findings need to be confirmed by larger clinical trials of methylene blue infused in a dose-titrated manner.en_US
dc.identifier.doi10.1177/0310057X0203000606
dc.identifier.endpage762en_US
dc.identifier.issn0310-057X
dc.identifier.issue6en_US
dc.identifier.pmid12500513en_US
dc.identifier.scopus2-s2.0-0036906749en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage755en_US
dc.identifier.urihttps://doi.org/10.1177/0310057X0203000606
dc.identifier.urihttps://hdl.handle.net/20.500.14551/22437
dc.identifier.volume30en_US
dc.identifier.wosWOS:000179795400006en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherAustralian Soc Anaesthetistsen_US
dc.relation.ispartofAnaesthesia And Intensive Careen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectMethylene Blue : Sepsis, Cytokine Levels, Haemodynamic Parameters, Intensive Care Uniten_US
dc.subjectNitric-Oxide Synthaseen_US
dc.subjectNecrosis-Factor-Alphaen_US
dc.subjectHuman Septic Shocken_US
dc.subjectVascular-Resistanceen_US
dc.subjectEndotoxin-Shocken_US
dc.subjectCyclic-Gmpen_US
dc.subjectInhibitionen_US
dc.subjectMedicineen_US
dc.titleThe influence of methylene levels during severe sepsis blue infusion on cytokineen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu